Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32835246
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
The immunology of COVID-19: is immune modulation an option for treatment?
#MMPMID32835246
Zhong J
; Tang J
; Ye C
; Dong L
Lancet Rheumatol
2020[Jul]; 2
(7
): e428-e436
PMID32835246
show ga
In December, 2019, an outbreak of COVID-19 emerged in Wuhan, China and quickly
spread globally. As of May 7, 2020, there were 3?672?238 confirmed infections and
254?045 deaths attributed to COVID-19. Evidence has shown that there are
asymptomatic carriers of COVID-19 who can transmit the disease to others. The
virus incubation time shows a wide range (0-24 days) and the virus displays a
high infectivity. It is therefore urgent to develop an effective therapy to treat
patients with COVID-19 and to control the spread of the causative agent, severe
respiratory syndrome coronavirus 2. Repurposing of approved drugs is widely
adopted to fight newly emerged diseases such as COVID-19, as these drugs have
known pharmacokinetic and safety profiles. As pathological examination has
confirmed the involvement of immune hyperactivation and acute respiratory
distress syndrome in fatal cases of COVID-19, several disease-modifying
anti-rheumatic drugs (DMARDS), such as hydroxychloroquine and tocilizumab, have
been proposed as potential therapies for the treatment of COVID-19. In this
Review, we discuss the immunological aspects of COVID-19 and the potential
implication of DMARDs in treating this disease.
free
free
free
